Travere Therapeutics, Inc. (TVTX)

NASDAQ: TVTX · IEX Real-Time Price · USD
7.71
+0.04 (0.52%)
Mar 28, 2024, 4:00 PM EDT - Market closed
0.52%
Market Cap 579.11M
Revenue (ttm) 145.24M
Net Income (ttm) -111.40M
Shares Out 76.10M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 698,158
Open 7.74
Previous Close 7.67
Day's Range 7.41 - 7.98
52-Week Range 5.25 - 23.18
Beta 0.59
Analysts Buy
Price Target 17.83 (+131.26%)
Earnings Date May 2, 2024

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurrin... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Eric M. Dube Ph.D.
Employees 380
Stock Exchange NASDAQ
Ticker Symbol TVTX
Full Company Profile

Financial Performance

In 2023, TVTX's revenue was $145.24 million, an increase of 32.69% compared to the previous year's $109.46 million. Losses were -$111.40 million, -60.00% less than in 2022.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is $17.83, which is an increase of 131.26% from the latest price.

Price Target
$17.83
(131.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted inducement ...

15 days ago - GlobeNewsWire

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

Travere announces submission of an sNDA to the FDA for conversion of existing US accelerated approval of FILSPARI (sparsentan) in IgAN to full approval.

17 days ago - GlobeNewsWire

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in March:

4 weeks ago - GlobeNewsWire

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe

4 weeks ago - GlobeNewsWire

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive...

4 weeks ago - PRNewsWire

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Received 459 new patient start forms (PSFs) for FILSPARI ® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023

6 weeks ago - GlobeNewsWire

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15, 2024...

6 weeks ago - GlobeNewsWire

Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim 6th Annual Biotechnology Conference on Thu...

7 weeks ago - GlobeNewsWire

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsent...

2 months ago - GlobeNewsWire

Travere Therapeutics Provides Corporate Update and 2024 Outlook

Received 459 new patient start forms for FILSPARI ® (sparsentan) in the fourth quarter of 2023; preliminary net product sales of FILSPARI totaled $15 million for the fourth quarter

2 months ago - GlobeNewsWire

Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P...

3 months ago - GlobeNewsWire

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026 Potential for pegtibatinase to become first disease-modifying treatment for cla...

3 months ago - GlobeNewsWire

Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tues...

4 months ago - GlobeNewsWire

Travere Therapeutics Reports Third Quarter 2023 Financial Results

Received 430 new patient start forms for FILSPARI ®  (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow

5 months ago - GlobeNewsWire

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape

5 months ago - GlobeNewsWire

Travere Therapeutics to Report Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close...

5 months ago - GlobeNewsWire

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI ® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS

5 months ago - GlobeNewsWire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2023, the Compensation Committee of its Board of Directors granted inducement...

6 months ago - GlobeNewsWire

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study ...

6 months ago - GlobeNewsWire

Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trial

Travere Therapeutics Inc. shares TVTX dropped 37% premarket on Thursday after the company released data from a late-stage study of Filspari in IgA nephropathy, a rare kidney disease. In a head-to-head...

6 months ago - Market Watch

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline two-year confirmatory secondary endpoint results from the Company's pivotal head-to-head...

6 months ago - GlobeNewsWire

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

• Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments • Mirum has acquired Travere's rights and assets related to Cholbam ® and ...

7 months ago - GlobeNewsWire

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Thera...

Other symbols: MIRM
7 months ago - Business Wire

Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference

SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday, S...

7 months ago - GlobeNewsWire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therape...

7 months ago - Accesswire